| scholarly article | Q13442814 |
| P356 | DOI | 10.7326/0003-4819-112-9-678 |
| P698 | PubMed publication ID | 2110430 |
| P50 | author | Antonio Ceriello | Q30347888 |
| P2093 | author name string | Giugliano D | |
| Consoli G | |||
| Magno M | |||
| Caretta F | |||
| Nardozza A | |||
| Quatraro A | |||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hydroxychloroquine | Q421094 |
| P304 | page(s) | 678-681 | |
| P577 | publication date | 1990-05-01 | |
| P1433 | published in | Annals of Internal Medicine | Q564416 |
| P1476 | title | Hydroxychloroquine in decompensated, treatment-refractory noninsulin-dependent diabetes mellitus. A new job for an old drug? | |
| P478 | volume | 112 |
| Q34389286 | A favorable effect of hydroxychloroquine on glucose and lipid metabolism beyond its anti-inflammatory role |
| Q40569580 | Antidiabetic and antimalarial biguanide drugs are metal-interactive antiproteolytic agents |
| Q36073241 | Antidiabetogenic effects of hydroxychloroquine on insulin sensitivity and beta cell function: a randomised trial |
| Q34226976 | Antimalarial therapy: a panacea for mild lupus? |
| Q34604474 | Antimalarials in cutaneous lupus erythematosus: mechanisms of therapeutic benefit |
| Q34129797 | Antimalarials. |
| Q41939554 | Antimalarials. A treatment option for every lupus patient!? |
| Q51031046 | Biochemical characterization of ADP-ribose polymer metabolism in SLE. |
| Q92037499 | COVID-19 and diabetes management: What should be considered? |
| Q47940789 | Cardiovascular disease in rheumatoid arthritis: medications and risk factors in China |
| Q34354276 | Changes in glycosylated hemoglobin after initiation of hydroxychloroquine or methotrexate treatment in diabetes patients with rheumatic diseases |
| Q30465023 | Chloroquine does not exert insulin-like actions on human forearm muscle metabolism |
| Q41934971 | Chloroquine reduces whole body proteolysis in humans |
| Q38845570 | Cooling down inflammation in type 2 diabetes: how strong is the evidence for cardiometabolic benefit? |
| Q54218397 | Current and Future Use of Chloroquine and Hydroxychloroquine in Infectious, Immune, Neoplastic, and Neurological Diseases: A Mini-Review. |
| Q46490126 | Discontinuation rate and factors predictive of the use of hydroxychloroquine in LUMINA, a multiethnic US cohort (LUMINA XL). |
| Q95529015 | Drug approvals in India |
| Q41926143 | Effect of experimental diabetes mellitus and arthritis on the pharmacokinetics of hydroxychloroquine enantiomers in rats |
| Q35742831 | Effect of hydroxychloroquine on insulin sensitivity and lipid parameters in rheumatoid arthritis patients without diabetes mellitus: a randomized, blinded crossover trial |
| Q87586879 | Effect of methotrexate use and erythrocyte methotrexate polyglutamate on glycosylated hemoglobin in rheumatoid arthritis |
| Q41937419 | Five-compartment model of insulin kinetics and its use to investigate action of chloroquine in NIDDM. |
| Q68235552 | Height and glucose tolerance |
| Q36240425 | Hydroxychloroquine Blood Levels in Systemic Lupus Erythematosus: Clarifying Dosing Controversies and Improving Adherence |
| Q36277899 | Hydroxychloroquine and glycemia in women with rheumatoid arthritis and systemic lupus erythematosus |
| Q35519392 | Hydroxychloroquine as a glucose lowering drug |
| Q53609113 | Hydroxychloroquine for the prevention of recurrent cardiovascular events in myocardial infarction patients: rationale and design of the OXI trial. |
| Q41915768 | Hydroxychloroquine hindering of diabetic isletopathy carries its signature on the inflammatory cytokines. |
| Q36246086 | Hydroxychloroquine improves insulin sensitivity in obese non-diabetic individuals |
| Q96768081 | Hydroxychloroquine, COVID-19 and diabetes. Why it is a different story |
| Q41953362 | Hydroxychloroquine: a diabetic drug in disguise? |
| Q37827403 | Hydroxychloroquine: from malaria to autoimmunity |
| Q38927961 | Immune-Modulating Therapy for Rheumatologic Disease: Implications for Patients with Diabetes |
| Q41924532 | Inhibition of insulin metabolism by hydroxychloroquine and its enantiomers in cytosolic fraction of liver homogenates from healthy and diabetic rats |
| Q41922948 | Insulin-sparing effect of hydroxychloroquine in diabetic rats is concentration dependent |
| Q35153962 | Management of Non-Insulin-Dependent Diabetes Mellitus |
| Q41941938 | Mode of action of chloroquine in patients with non-insulin-dependent diabetes mellitus |
| Q92170354 | NURR1 activation in skeletal muscle controls systemic energy homeostasis |
| Q52316454 | Protective Effects of Hydroxychloroquine against Accelerated Atherosclerosis in Systemic Lupus Erythematosus. |
| Q96953776 | SARS-CoV-2 disease severity and diabetes: why the connection and what is to be done? |
| Q98383294 | Safety of hydroxychloroquine in COVID-19 and other diseases: a systematic review and meta-analysis of 53 randomized trials |
| Q34291268 | Sarcoidosis - a clinically orientated review |
| Q41941207 | Steady-State Pharmacokinetics of Hydroxychloroquine in Rheumatoid Arthritis Patients |
| Q41942343 | Stereoselective determination of hydroxychloro-quine and its major metabolites in human urine by solid-phase microextraction and HPLC. |
| Q35607534 | Stereoselectivity in the pharmacodynamics and pharmacokinetics of the chiral antimalarial drugs. |
| Q41919952 | Steroid-induced diabetes mellitus in systemic lupus erythematosus patients: analysis from a Malaysian multi-ethnic lupus cohort |
| Q24186660 | Sulphonylurea monotherapy for patients with type 2 diabetes mellitus |
| Q24197884 | Sulphonylurea monotherapy for patients with type 2 diabetes mellitus |
| Q41912319 | Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual |
| Q88447728 | Targeting autophagy in obesity: from pathophysiology to management |
| Q37261219 | The effect of hydroxychloroquine on glucose control and insulin resistance in the prediabetes condition |
| Q41917902 | The effectiveness of hydroxychloroquine in patients with type 2 diabetes mellitus who are refractory to sulfonylureas--a randomized trial |
| Q36240014 | Type II Diabetes and Syndrome X: Pathogenesis and Glycemic Management |
| Q84600129 | [Antimalarials: an update in rheumatic diseases] |
| Q87117771 | [Multimorbidity in elderly rheumatic patients part 2] |
Search more.